loading
前日終値:
$4.37
開ける:
$4.41
24時間の取引高:
9.92M
Relative Volume:
0.66
時価総額:
$1.89B
収益:
$285.55M
当期純損益:
$-353.86M
株価収益率:
-4.4522
EPS:
-0.9501
ネットキャッシュフロー:
$-305.02M
1週間 パフォーマンス:
-1.86%
1か月 パフォーマンス:
+11.90%
6か月 パフォーマンス:
+72.65%
1年 パフォーマンス:
+119.17%
1日の値動き範囲:
Value
$4.145
$4.45
1週間の範囲:
Value
$4.07
$4.5399
52週間の値動き範囲:
Value
$1.70
$5.63

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name
名前
Iovance Biotherapeutics Inc
Name
セクター
Healthcare (1096)
Name
電話
(650) 260-7120
Name
住所
825 INDUSTRIAL ROAD, SAN CARLOS
Name
職員
975
Name
Twitter
Name
次回の収益日
2026-08-06
Name
最新のSEC提出書
Name
IOVA's Discussions on Twitter

Compare IOVA vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IOVA icon
IOVA
Iovance Biotherapeutics Inc
4.23 1.89B 285.55M -353.86M -305.02M -0.9501
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
485.39 123.19B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
664.52 69.67B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
877.62 54.58B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
298.76 39.89B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
186.88 39.73B 742.00K -1.37B -1.07B -7.0731

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-25 アップグレード Citizens Mkt Perform → Mkt Outperform
2025-07-15 ダウングレード Goldman Neutral → Sell
2025-05-16 ダウングレード UBS Buy → Neutral
2025-05-12 ダウングレード Truist Buy → Hold
2025-05-09 ダウングレード Citizens JMP Mkt Outperform → Mkt Perform
2024-10-24 開始されました UBS Buy
2024-07-29 ダウングレード Piper Sandler Overweight → Neutral
2023-11-20 開始されました Goldman Buy
2023-09-18 繰り返されました Barclays Overweight
2023-05-30 アップグレード Wells Fargo Equal Weight → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-27 アップグレード Piper Sandler Neutral → Overweight
2022-12-09 ダウングレード Goldman Buy → Neutral
2022-10-31 開始されました Guggenheim Neutral
2022-08-18 再開されました Wells Fargo Equal Weight
2022-01-28 アップグレード Stifel Hold → Buy
2021-12-07 再開されました Cowen Outperform
2021-06-10 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2021-05-20 ダウングレード Piper Sandler Overweight → Neutral
2021-05-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2021-05-19 ダウングレード Stifel Buy → Hold
2021-05-03 開始されました Truist Buy
2021-04-16 開始されました Goldman Buy
2021-03-08 アップグレード H.C. Wainwright Neutral → Buy
2020-12-15 ダウングレード H.C. Wainwright Buy → Neutral
2020-10-06 ダウングレード Wells Fargo Overweight → Equal Weight
2020-04-22 開始されました Mizuho Buy
2020-03-04 開始されました Barclays Overweight
2020-02-26 繰り返されました H.C. Wainwright Buy
2020-02-26 繰り返されました Oppenheimer Outperform
2019-12-18 開始されました JMP Securities Mkt Outperform
2019-10-01 開始されました Stifel Buy
2019-04-29 開始されました Piper Jaffray Overweight
2019-02-28 繰り返されました Chardan Capital Markets Buy
2019-02-07 開始されました Robert W. Baird Outperform
2018-12-31 再開されました B. Riley FBR Buy
2018-07-06 繰り返されました Chardan Capital Markets Buy
2018-04-10 アップグレード B. Riley FBR, Inc. Neutral → Buy
2018-03-13 繰り返されました B. Riley FBR, Inc. Neutral
2018-02-23 ダウングレード B. Riley FBR, Inc. Buy → Neutral
2018-01-25 繰り返されました H.C. Wainwright Buy
2017-11-01 繰り返されました B. Riley FBR, Inc. Buy
すべてを表示

Iovance Biotherapeutics Inc (IOVA) 最新ニュース

pulisher
Jul 11, 2026

Iovance Biotherapeutics (IOVA) Could Be 76% Undervalued Following Its Refreshed Growth Narrative - Sahm

Jul 11, 2026
pulisher
Jul 10, 2026

Why Is IOVA Stock Falling Today? - Stocktwits

Jul 10, 2026
pulisher
Jul 09, 2026

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits

Jul 09, 2026
pulisher
Jul 09, 2026

Iovance Biotherapeutics (IOVA) Updates its Corporate Presentation, Here’s What’s Important to Note - Insider Monkey

Jul 09, 2026
pulisher
Jul 09, 2026

IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits

Jul 09, 2026
pulisher
Jul 08, 2026

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com

Jul 08, 2026
pulisher
Jul 08, 2026

This Stock Is Up 74% This Year: Is It Too Late to Buy? - The Motley Fool

Jul 08, 2026
pulisher
Jul 07, 2026

Enterprise value to revenue forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView

Jul 07, 2026
pulisher
Jul 07, 2026

Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits

Jul 07, 2026
pulisher
Jul 06, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 06, 2026
pulisher
Jul 05, 2026

IOVAIovance Biotherapeutics Inc Options - Finviz

Jul 05, 2026
pulisher
Jul 02, 2026

Iovance Biotherapeutics updates corporate presentation, reiterates $350M–$370M FY26 guidance - TradingView

Jul 02, 2026
pulisher
Jul 02, 2026

Iovance Biotherapeutics (IOVA) projects 2026 revenue of $350M–$370M and cash runway into 2028 - Stock Titan

Jul 02, 2026
pulisher
Jul 02, 2026

IOVA Stock Price, Quote & Chart - ChartMill

Jul 02, 2026
pulisher
Jun 30, 2026

IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits

Jun 30, 2026
pulisher
Jun 29, 2026

IOVA News | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill

Jun 29, 2026
pulisher
Jun 29, 2026

IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen - ChartMill

Jun 29, 2026
pulisher
Jun 28, 2026

Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus

Jun 28, 2026
pulisher
Jun 28, 2026

REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits

Jun 28, 2026
pulisher
Jun 27, 2026

Enterprise value to revenue forward of Iovance Biotherapeutics Inc – SWB:2LB - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Urged to Join - The National Law Review

Jun 27, 2026
pulisher
Jun 27, 2026

Why Iovance Biotherapeutics (IOVA) Is Up 7.7% After Australian Conditional OK For Amtagvi Cell Therapy - Sahm

Jun 27, 2026
pulisher
Jun 27, 2026

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Ge - The National Law Review

Jun 27, 2026
pulisher
Jun 27, 2026

Investor Alert: Deadline Approaching to Join Iovance Biotherapeut - The National Law Review

Jun 27, 2026
pulisher
Jun 27, 2026

IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics - The National Law Review

Jun 27, 2026
pulisher
Jun 27, 2026

IOVA Stockholders Have Opportunity to Lead Iovance Biotherapeutic - The National Law Review

Jun 27, 2026
pulisher
Jun 27, 2026

Enterprise value to EBIT forward of Iovance Biotherapeutics Inc – SWB:2LB - TradingView

Jun 27, 2026
pulisher
Jun 26, 2026

Price to sales forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Price to sales forward of Iovance Biotherapeutics Inc – LS:A2DT49 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Price to book forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Price to earnings forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to EBITDA forward of Iovance Biotherapeutics Inc – LS:A2DT49 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Price to earnings forward of Iovance Biotherapeutics Inc – LS:A2DT49 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Price to book forward of Iovance Biotherapeutics Inc – LS:A2DT49 - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

Iovance Biotherapeutics Inc Actuals & Estimates (NASDAQ:IOVA) - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

Iovance Biotherapeutics (IOVA) Wins Australia Approval For Amtagvi In Melanoma - Sahm

Jun 25, 2026
pulisher
Jun 24, 2026

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com

Jun 24, 2026
pulisher
Jun 23, 2026

5 Resilient Stocks During Market Bloodbath - Insider Monkey

Jun 23, 2026
pulisher
Jun 23, 2026

Iovance (IOVA) Surges 9.4% on Regulatory Nod - Insider Monkey

Jun 23, 2026
pulisher
Jun 23, 2026

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Jun 23, 2026
pulisher
Jun 23, 2026

Iovance (NASDAQ:IOVA) gains after $89.7 million stock sale - TechStock²

Jun 23, 2026
pulisher
Jun 23, 2026

IOVA Stock Climbs As Amtagvi Wins Australia Nod And Pipeline Expands - StocksToTrade

Jun 23, 2026
pulisher
Jun 22, 2026

Iovance Biotherapeutics (IOVA) Stock Could Be 53.2% Undervalued After New Shelf Filings - Sahm

Jun 22, 2026

Iovance Biotherapeutics Inc (IOVA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$56.43
price down icon 2.64%
$115.61
price down icon 2.24%
$35.97
price down icon 2.28%
$68.27
price down icon 10.83%
ONC ONC
$298.70
price down icon 1.36%
$186.88
price down icon 2.22%
大文字化:     |  ボリューム (24 時間):